Insilico Medicine is advancing to Phase III human trials for testing a drug identified by AI targeting idiopathic pulmonary fibrosis (IPF). This progression supplies the computational drug discovery sector with empirical test cases, advancing an AI medicine past early safety evaluations into late-stage efficacy validation.
IPF destroys respiratory capacity through severe lung tissue scarring. Patients typically present a median survival rate reaching two to four years post-diagnosis. The AI-identified drug, rentosertib, inhibits the TRAF2- and NCK-interacting kinase to address underlying disease mechanisms when administered orally.
A randomised trial evaluated 71 patients across 22 Chinese clinical sites, separating participants into placebo and active treatment cohorts. Investigators administered 30 mg or 60 mg daily doses over a 12-week observation window.
Patients assigned to the 60 mg once-daily regimen demonstrated a mean forced vital capacity gain of +98.4 mL, contrasting sharply with the 20.3 mL capacity loss recorded in the placebo group. Safety profiles remained manageable, with adverse events mirroring expected baseline rates across all trial arms. Regulatory authorities at the U.S. Food and Drug Administration (FDA) granted ‘Orphan Drug Designation’ to the asset in February 2023.
Algorithmic target prioritisation through multi-omicsThe development relies entirely on Pharma.AI, the proprietary computational pipeline operating at Insilico Medicine. The workflow segments into distinct engines handling specific biological and chemical engineering tasks.
PandaOmics executes the initial target discovery phase. The system ingests vast biological datasets, processing genomics, clinical trial outcomes, academic literature, and patent intelligence to construct comprehensive biological network models. The algorithms apply causal inference mechanisms to identify novel disease links hidden within the data architecture.
PandaOmics isolated TNIK as the primary biological target regarding IPF intervention. The computational system bypassed the receptor tyrosine kinase pathways targeted by existing antifibrotic medications.
The software mapped TNIK as a central node regulating fibrosis and inflammation via Wnt, TGF-β, Hippo/YAP-TAZ, JNK, and NF-κB signalling channels. The target selection process integrated a hallmarks-of-aging framework, scoring biological targets based on their implication in multiple aging mechanisms, chronic inflammation, and extracellular matrix remodelling.
Feng Ren, PhD, Co-CEO and Chief Scientific Officer of Insilico Medicine, said: “IPF is one of the clearest clinical examples of an age-related disease in which fibrosis, chronic inflammation, extracellular matrix remodeling, and cellular senescence intersect.
“Rentosertib was not discovered by starting from a conventional target and simply screening more compounds. It came from a biology-first, ageing-informed AI workflow that connected TNIK to fibrotic and inflammatory disease mechanisms, and then used generative chemistry to create a drug candidate with the properties required for clinical development.”
Generative molecular engineering executionFollowing target selection, the Chemistry42 engine executes generative molecular design. The system departs from traditional high-throughput screening methodologies. Chemistry42 does not search existing compound libraries—instead, the system applies Generative Tensorial Reinforcement Learning to build molecules that physically align with the target protein pocket. This algorithmic engineering process balances structural fit against required pharmacological properties.
The computational generation phase synthesised exactly 79 physical molecules to undergo testing. The engineering team selected the 55th iteration to advance into preclinical testing. This targeted generation protocol reduced the timeline from project initiation to preclinical candidate nomination to 18 months.
The foundational architecture stems from the 2019 publication of the company’s GENTRL methodology in Nature Biotechnology. The platform establishes reproducible systems regulating molecular generation, avoiding the capital-intensive trial-and-error processes defining standard pharmaceutical chemistry.
Validating biological impact through proteomic analysisClinical assessment integrates complex proteomic analysis to validate the algorithmically-predicted biological interactions. Insilico Medicine deploys internal proteomic aging-clock frameworks within the IPF trial to capture exploratory geroscience readouts.
Chronological-age proteomic clocks – including ProtAge, OrganAgechrono, ipfP3GPT, and PAOPAC – track predicted biological-age changes resulting from the intervention. Researchers apply UK Biobank age-associated trajectories as external comparison datasets, contextualising treatment-responsive proteins against broad population data.
Mortality-risk-related proteomic clocks, including PAC and OrganAgemortality, provide orthogonal analytical streams alongside standard clinical endpoints. The clinical teams execute SenMayo and CellAge signature analyses to evaluate senescence and senescence-associated secretory phenotype biology within cellular models.
Peer-reviewed research published in Aging and Disease confirmed that pharmacological TNIK inhibition produces senomorphic activity, generating observable reductions in extracellular matrix remodelling indicators.
Documenting the computational pipelineThe transition of rentosertib through the clinical pipeline provides a documented, peer-reviewed data trail essential to verifying AI capabilities in life sciences. Nature Biotechnology published the complete discovery-to-clinic progression. The publication details the algorithmic TNIK target prioritisation, the generative chemistry outputs, preclinical efficacy data, and human Phase I pharmacokinetics.
The Journal of Medicinal Chemistry published the structural biology validation, detailing the discovery of the novel TNIK inhibitor chemotypes and supplying structural backing via the TNIK kinase domain co-crystal structure. Nature Medicine documented the Phase IIa safety and lung-function data, providing empirical validation of the computational predictions.
Alex Zhavoronkov, PhD, Founder and CEO of Insilico Medicine, commented: “Rentosertib is a defining program for Insilico because it represents the full arc of our mission: using AI not only to move faster, but to originate new biology, new chemistry, and new therapeutic opportunities.
“This program began with the hypothesis that ageing biology could help identify powerful targets for major diseases. It has now advanced through target discovery, molecular design, preclinical validation, Phase I safety, randomised Phase IIa clinical data, and into Phase III development. For the AI drug discovery field, this is no longer only a speed story—it is a clinical translation story.”
Adoption of AI in biopharma requires verifiable data regarding human outcomes. The Phase III trial subjects the generative algorithms to the definitive test of clinical efficacy.
See also:NVIDIA BioNeMo accelerates Anthropic Claude Science
Want to learn more about AI and big data from industry leaders? Check out AI & Big Data Expo taking place in Amsterdam, California, and London. The comprehensive event is part of TechEx and is co-located with other leading technology events including the Cyber Security & Cloud Expo. Click here for more information.
AI News is powered by TechForge Media. Explore other upcoming enterprise technology events and webinars here.
The post Insilico Medicine advances AI drug for IPF to Phase III trials appeared first on AI News.